QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer Austin, TX, April 05, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...

QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer Austin, TX, Dec. 01, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...

QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment...

QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma Austin, TX, Aug. 18, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment...

Q2Earth Appoints Douglas Baum, Senior Biosciences Executive, To Board of Directors Palm Beach, FL, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Q2Earth, Inc. (OTCQB: QPWR) (the “Company” or “Q2”) announced today that it has appointed Douglas R. Baum to its Board of Directors. Mr. Baum...